Frequency of cytokine gene promoter polymorphisms in the Northern Ireland Cystic Fibrosis population  by Watt, Alison P. et al.
Journal of Cystic Fibrosis 6 (2007) 363–365
www.elsevier.com/locate/jcfShort communication
Frequency of cytokine gene promoter polymorphisms in the Northern
Ireland Cystic Fibrosis population
Alison P. Watt a,⁎, Owen A. Ross b,c, Julia Courtney a, Derek Middleton b,
Madeleine Ennis a, J. Stuart Elborn a
a Respiratory Research Group, The Queen's University of Belfast, United Kingdom
b Northern Ireland Regional Histocompatibility and Immunogenetics Laboratory, City Hospital, Belfast, Northern Ireland, United Kingdom
c School of Biology and Biochemistry, Queens University of Belfast, Northern Ireland, United Kingdom
Received 23 October 2006; received in revised form 11 December 2006; accepted 19 January 2007
Available online 1 March 2007Abstract
It has been postulated that cytokine allele frequencies are gender and perhaps geographically-specific. Cytokine release is crucial in the
regulation of the type and magnitude of the immune response. This study observed no differences in the frequency of cytokine promoter
polymorphisms associated with variant levels of expression in patients with CF and a non-CF population of Northern Ireland.
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Over 1000 mutations have been identified in the
transmembrane conductance regulator gene (CFTR;
OMIM⁎602421), 75–80% of which are accounted for by
the 3 base pair deletion delta F508. CFTR mutations have
been observed to cause a wide spectrum of phenotypes,
indeed patients with the same mutation and even from the
same family, can present with alternate phenotypes [1].
Cloning of the CFTR gene has promoted extensive research
into genotype and phenotype correlation [2,3]. Whilst
pancreatic disease in CF sufferers is closely related to
specific mutations, there is significant variation in lung
disease severity and progression among patients which is not
related to the basic defect in the CFTR gene [4]. These
findings indicate that other genetic/environmental factors
modify the disease phenotype. Modifier gene frequency
evolves in such a way to maximize the mean fitness of the⁎ Corresponding author. Microbiology Kelvin Building Belfast BT12
6BA 028 90632111.
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doi:10.1016/j.jcf.2007.01.002population at equilibrium [5]. With regard to the CF
population, as cytokine SNP's potentially influence the
inflammatory response and therefore the susceptibility of the
individual to developing severe or mild lung disease, it may
be expected that allele frequencies may differ from the non-
CF population.
CF lung disease is characterised by persistent bacterial
infection with severe and sustained neutrophil-mediated
inflammation [6]. Cytokines play an important role in the
pathophysiology of CF lung disease with cytokine dysregu-
lation demonstrated in CF airway cells and circulating
inflammatory cells [7,8]. In several cytokine genes, poly-
morphisms (mostly single nucleotide polymorphisms
(SNP's) or microsatellites) located within the critical
promoter or other regulatory regions, affect gene transcrip-
tion resulting in inter-individual variation in levels of
cytokine production [9].
In the present study a range of polymorphisms were chosen
within the promoter region of the cytokines genes; IL-2, IL-6,
IL-8, IL-10 and TNFα (see Table 1). Previous studies have
demonstrated that these polymorphisms are associated with
variant levels of cytokine production [10–14]. The frequencyed by Elsevier B.V. All rights reserved.
Table 1
Position, association and polymorphism in each of the cytokine genes
Cytokine Nucleotide
position
Polymorphism High producer
allele
Analysis
IL-2 −330 T→ G G SSOP
IL-6 −174 C → G G SSOP
IL-8 −251 A→ T A SSOP
IL-10 −1082 G→ A G SSOP
TNFα −308 G→ A A SSOP
Table 2
The observed allele and genotype frequencies for the polymorphic markers
of the cytokine genes; IL-2, IL-6, IL-8, IL-10 and TNFα
Controls n=100 Cystic Fibrosis n=101
Male
n=41 (%)
Female
n=59 (%)
Total
(%)
Male
n=50 (%)
Female
n=51 (%)
Total
(%)
IL-2
GG 6 (15) 8 (14) 14 (14) 8 (16) 7 (14) 15 (15)
GT 17 (41) 31 (53) 48 (48) 16 (32) 21 (42) 37 (37)
TT 18 (44) 20 (34) 38 (38) 27 (54) 22 (44) 49 (49)
G 29 (35) 47 (40) 76 (38) 32 (42) 35 (35) 67 (33)
T 53 (65) 71 (60) 124 (62) 45 (58) 65 (65) 135 (67)
IL-6
GG 16 (39) 13 (22) 29 (29) 25 (50) 14 (27) 39 (39)
GC 18 (44) 31 (53) 49 (49) 22 (44) 27 (53) 49 (49)
CC 7 (17) 15 (25) 22 (22) 3 (6) 10 (20) 13 (13)
G 50 (32) 57 (48) 107 (54) 72 (72) 55 (54) 127 (63)
C 32 (39) 61 (52) 93 (46) 28 (28) 47 (46) 75 (37)
IL-8
AA 12 (29) 13 (22) 25 (25) 11 (22) 12 (24) 23 (23)
AT 18 (44) 27(46) 45 (45) 28 (56) 21 (41) 49 (49)
TT 11 (27) 19 (32) 30 (30) 11 (22) 18 (35) 29 (18)
A 42 (51) 53 (45) 95 (47) 50 (50) 45 (44) 95 (47)
T 40 (49) 65 (55) 105 (53) 50 (50) 57 (56) 107 (53)
IL-10
GG 15 (37) 19 (32) 34 (34) 12 (24) 22 (43) 34 (34)
GA 18 (44) 29 (49) 47 (47) 27 (54) 16 (31) 43 (43)
AA 8 (20) 11(19) 19 (19) 11 (22) 13 (26) 24 (24)
G 48 (59) 67 (57) 115 (58) 51 (51) 60 (59) 111 (55)
A 34 (41) 51 (43) 85 (42) 49 (49) 42 (41) 91 (45)
TNFα
GG 28 (68) 33 (56) 61 (61) 32 (48) 34 (52) 66 (66)
AG 11 (27) 21 (36) 32 (32) 13 (41) 19 (59) 32 (32)
AA 2 (5) 5 (8) 7 (7) 2 (67) 1 (33) 3 (3)
G 28 (34) 87 (74) 154 (77) 77 (82) 87 (81) 164 (81)
A 15 (18) 31 (26) 46 (23) 17 (18) 21 (19) 38 (19)
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potential association with CF lung disease in the Northern
Ireland population.
2. Subjects and methods
One hundred and one patients with CF (51% female, 49%
male, age-range of 20–53 years) participated in this study. A
diagnosis of CF was confirmed by a typical phenotype,
genotype and/or sweat test. Of these patients with CF, 34
were ΔF508 homozygous, 35 were heterozygous ΔF508
and 32 had other mutations. One hundred control samples
(59% female, 41% male with an age-range of 19–45 years)
were chosen at random from the DNA bank of normal
healthy Caucasian individuals from the Northern Ireland
population (data previously published [15,16]. These
samples were stored within the Northern Ireland Histocom-
patibility and Immunogenetics Laboratory (NIHIL) of
Belfast City Hospital.
3. Analysis of IL-2, IL-6, IL-8, IL-10 and TNFα
polymorphisms by SSOP
PCR amplification using the appropriate primer pairs for
each target region was performed as previously described
[15,16]. Successful amplification was confirmed using gel
electrophoresis on a 1% agarose gel stained with ethidium
bromide (0.5 μg/ml). Amplified DNA (2 μl) was applied to a
charged nylon membrane as previously reported [17].
Hybridisations, stringent washes and chemiluminescence
detection of the hybridised digoxigenin (DIG)-labelled
probes were carried out as reported [18]. The DNA
sequences of the probes were broadly designed on the
basis of a central location for the polymorphic nucleotide.
Stringent wash temperatures and concentrations for each of
the probes were empirically determined [18].
4. Statistical analysis
Fisher's Exact probability tests were performed to assess
the frequency differences observed between the CF and
control groups were statistically significant. All genotype
distributions of patients and controls were in Hardy–
Weinberg equilibrium ruling out population stratification of
the patient groups.5. Results
The frequency of a cross-section of polymorphisms
occurring within a number of cytokine genes were
investigated in a cohort of Northern Ireland Cystic Fibrosis
patients in comparison to a control group from the Northern
Ireland population. The genotype and allele frequencies
observed for the polymorphic markers in the genes of IL-2,
IL-6, IL-8, IL-10 and TNFα are displayed in Table 2. There
was no obvious genotype frequency difference observed
when the cohort of Cystic Fibrosis patients was compared to
control group, or when analyzed with respect to gender.
6. Discussion
This is the first report comparing the frequency of the
cytokine polymorphisms in the CF population in Northern
Ireland. Although no association was observed for the
polymorphic cytokine markers and Cystic Fibrosis the
analysis of genetic factors other than CFTR may assist in
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tionships in CF. In several cytokine genes, polymorphisms
located within the critical promoter or other regulatory
regions, affect gene transcription resulting in inter-individual
variation in levels of cytokine production [9]. Avicious cycle
of infection and exaggerated inflammation occurs in CF lung
disease, pro-inflammatory cytokines in particular may play a
key role in damaging the host.
Northern Ireland has 380 patients (197 over 18 years of age)
with CF, approximately 36.5% are homozygous for the F508
deletion, 35.9% are heterozygous for the F508 deletion, 15.4%
have other mutations whilst the remaining 13.2% have
unknown mutations. The number of patients with CF in
Northern Ireland restricts research into polymorphism associ-
ated CF lung disease, as when performing genotype/
phenotype association studies it is necessary to exclude
variables which may affect the phenotype. For example, it is
important to include only patients who are homozygous for the
F508 deletion to exclude an effect of CFTR genotype on
disease [19]. Age is another important consideration as the
effect of a mutation may become more penetrant by age,
particularly so in the CF population since FEV% predicted
values will decline more rapidly with age than in the general
population [20].
Treatment centres are also a source of variability due to
different treatments andmeasurement of clinical variableswhich
could affect classification of disease status [20]. Infective micro-
bial status of patients has a profound effect on patient outcome,
pulmonary colonisation with Burkholderia cenocepacia has
been documented to lead to an accelerated decline in lung
function [21]. Following correction of the Northern Ireland CF
population for the variablesmentioned above group numbers are
too small to yield any meaningful outcome associations. Eval-
uation of possible interactions of these cytokine polymorphisms
with CF pulmonary disease has been limited by study size.
Measurement of cytokine levels in the two populations studied
would also confirm if comparable changes in cytokine produc-
tion were evident in patients and healthy subjects.
Large collaborative studies across European populations
are now warranted to fully exam the role of potential genetic
disease-modifiers. Segregation of samples on the basis of
both genetic background and environmental exposures (e.g.
infection) will allow the identification of homogeneous
groups. Cytokine polymorphisms and their relationship to
lung disease in patients with CF are now a focal point of
interest. The identification of genetic factors which influence
disease severity in CF may lead to targeted aggressive
therapy in those patients at risk of more severe disease [22].
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